静脉注射免疫球蛋白对神经病理性疼痛治疗作用的研究进展

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (2): 213-216.

静脉注射免疫球蛋白对神经病理性疼痛治疗作用的研究进展

王立凤¹, 张志宇², 李真真¹, 梁映霞¹

¹潍坊医学院麻醉学,潍坊261053,山东;
²寿光市人民医院显微创伤外科,潍坊261000,山东

收稿日期:2013-11-25 修回日期:2014-03-03 出版日期:2015-02-26 发布日期:2015-03-20
通讯作者: 梁映霞,女,博士,副教授,研究方向:躯体疼痛与治疗。Tel: 13963602002 E-mail: lyx@wfmc.edu.cn
作者简介:王立凤,女,硕士研究生,研究方向:神经病理性疼痛的免疫机制。Tel: 0536-8462471 E-mail: sgrmyy@163.com
基金资助:
山东省自然科学基金(ZR2012HL27);潍坊医学院科技创新研究基金(K11QC1001);国家自然科学基金(81300969);潍坊市科技局课题(20121373)

Research progress of therapy of intravenous immunoglobulin on neuropathic pain

WANG Li-feng¹, ZHANG Zhi-yu², LI Zhen-zhen¹, LIANG Ying-xia¹

¹Department of Anesthesiology, Weifang Medical University, Weifang 261053, Shandong,China;
²Department of Microsurgery, The People's Hospital of Shouguang, Weifang 262700, Shandong, China

Received:2013-11-25 Revised:2014-03-03 Online:2015-02-26 Published:2015-03-20

摘要/Abstract

摘要： 静脉注射免疫球蛋白具有多种免疫调节方面的功能,临床上常用于自身免疫性疾病的治疗。近年来,静脉注射免疫球蛋白也应用于许多神经系统疾病的治疗,因为部分神经系统疾病的发病机制与免疫调节相关。神经病理性疼痛是慢性顽固性的疼痛综合征,发病机制复杂,免疫调节也参与神经病理性疼痛的发生。目前发现静脉注射免疫球蛋白可以明显减轻神经病理性疼痛患者的疼痛,给药后无严重不良反应的发生,而且在镇痛的同时可以促进伤口的愈合,提高患者的生活质量。其作用机制可能是免疫球蛋白可以阻断自身抗体与Fc受体结合或中和自身抗体,减轻补体介导的组织损伤作用;还可以通过降低炎性细胞因子表达减轻患者的疼痛。

关键词: 镇痛, 免疫球蛋白, 免疫调节, 神经病理性疼痛

Abstract: Intravenous use of immunoglobulin exhibits many immuno-modulatory properties and has been used clinically to treat several autoimmune disease. Currently, immunoglobulin is being investigated as an immuno-modulatory therapy in many neurological diseases. Neuropathic pain is choronic intractable pain syndrome, which has complex mechanisms, immuno-modulatory involved. Recently, intravenous immunoglobulin has significant antinocicetptive effect on neuropahtic pain patients, without any serious adverse reactions. It improves functional recovery, and quality of life. The mechanism may be blocking immunoglobulin binding with Fc receptor or neutralizing antibodies to reduce the damage of complement-mediated; may also reduce inflammatory cytokines in patients with neurological disease.

Key words: analgesic, immunoglobulin, immuno-modulatory, neuropathic pain

中图分类号:

R741

王立凤, 张志宇, 李真真, 梁映霞. 静脉注射免疫球蛋白对神经病理性疼痛治疗作用的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 213-216.

WANG Li-feng, ZHANG Zhi-yu, LI Zhen-zhen, LIANG Ying-xia. Research progress of therapy of intravenous immunoglobulin on neuropathic pain[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 213-216.

参考文献

[1] 李招胜,林洪,沙漠,等.神经病理性疼痛的药物治疗研究进展[J].中国临床药理学与治疗学, 2013,18(9):1076-1080.
[2] Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain[J]. Br J Anaesth,2013,111(1):26-37.
[3] Napoli I, Noon LA, Ribeiro S, et al. A central role for the ERK signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo[J]. Neuron, 2012, 73(4): 729-742.
[4] Nicotra L, Loram LC, Watkins LR, et al. Toll-like receptors in chronic pain[J]. Exp Neurol,2012, 234(2): 316-329.
[5] Colton CA. Microglial-neuronal interactions during neurodegenerative diseases [J]. J Neuroimmune Pharmacol, 2013, 8(1):4-6.
[6] Olson JK. Immune response by microglia in the spinal cord[J]. Ann N Y Acad Sci, 2010, 1198:271-278.
[7] Liao YH, Zhang GH, Jia D, et al. Spinal astrocytic activation contributes to mechanical allodynia in a mouse model of type 2 diabetes[J]. Brain Res, 2011, 1368: 324-335.
[8] Goebel A. Immunoglobulin responsive chronic pain [J].J Clin Imuunol,2010,30(Suppl 1):S103-108.
[9] Kawagashira Y, Watanabe H, Morozumi S, et al.Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy[J].J Clin Neurosci,2010 (17):1003-1008.
[10]杨琴,杨军,李光勤.糖尿病炎性脱髓鞘性周围神经病---附5例报告[J].重庆医科大学学报,2005,30(2):315-317.
[11]Wakasugi D,Kato T, GonO T, et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathyassociated with primary Sjgren's syndrome[J].Mod Rheumatol,2009,19(4):437-440.
[12]Sharma, KR,Cross J, Ayyar DR, et al. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy[J].Arch Neurol,2002,59(5):751-757.
[13]Turner-Stokes L, Goebel A, Guideline Development Group. Complex Regional pain syndrome in adults:concise guidance[J]. Clin Med, 2011,11(6):596-600.
[14]Goebel A, Baranowski A, Maurer K, et al.Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial[J].Ann Intern Med,2010,152(3):152-158.
[15]Goebel A,Stock M, Deacon R, et al.Intravenous Immunoglobulin Response and Evidence for Pathogenic Antibodies in a case of complex regional pain syndrome 1[J]. Ann Neurol,2005,57(3):463-464.
[16]Vincent A. Unravelling the pathogenesis of myasthenia gravis[J].Nat Rev Immunol,2002,2(10):797-804.
[17]Hodgkin PD,Heath WR, Baxter AG. The clonal selection theory: 50 years since the revolution[J].Nat Immunol,2007,8(10):1019-1026.
[18]Werhagen L,Borg K. Effect of intravenous immunoglobulin on pain in patients with post-polio syndrome[J].J Rehabil Med,2011,43(11):1038-1040.
[19]Nguyen DH, Cho N, Satkunendrarajah K, et al. Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury[J]. J Neuroinflammation, 2012,9: 224.
[20]Jolles S, Hughes J,Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin[J]. Arch Dermatol,1998,134(1):80-86.
[21]瞿镔,许爱娥.静脉注射丙种球蛋白治疗重症带状疱疹4例[J].临床皮肤科杂志,2001,30(4):237-238.